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OBJECTIVES: Payers are increasingly concerned with assessing the value of 
pharmaceutical products to guide reimbursement and pricing decisions, and 
particularly in countries employing an HTA process, value is often largely based 
on clinical effectiveness measured as cost-per-QALY. The objective of this study 
is to assess how the EQ-5D index reacts across a broad range of conditions to 
clinical changes which are considered significant at the individual disease and 
patient level. METHODS: A systematic review of published studies assessing the 
psychometric properties of the EQ-5D, in particular studies reporting statistics on 
the responsiveness of the EQ-5D index. The Standardised Response Mean (SRM) 
and Effect Size (ES), which are both measures of signal-to-noise and describe the 
responsiveness of EQ-5D to clinical change, are compared to benchmark scores 
from the psychometric literature. We also compare the Visual Analogue Scale (VAS) 
self-reported health component against the EQ-5D index. RESULTS: In the majority 
of studies, the responsiveness of EQ-5D to clinical change overall was poor to 
moderate: In only approx. half of studies was the VAS score within 10% of the EQ-
5D index score. Ceiling effects of >15% at baseline where reported in half the studies 
examined. Only 25% of studies reported ES values within the range considered 
“moderate” to “good”, and 7% of studies reported SRM values in the “moderate” to 
“good” range. CONCLUSIONS: When considering widely accepted psychometric 
benchmarks and the relation between self-reported health and EQ-5D index, only a 
minority of studies (11%) report consistently good performance of the EQ-5D in 
reflecting clinically important changes. Consequently, a significant proportion of 
therapeutic value (both from a clinical and patient perspective) is not adequately 
captured by the existing EQ-5D framework. This has implications for the way new 
therapies have traditionally been assessed for value, particular as countries start 
moving towards value based pricing.  
 
PR3  
A CONTINGENT VALUATION SURVEY OF USER FINANCIAL INCENTIVES FOR 
HEALTH BEHAVIOUR CHANGE  
Meads DM, McCabe C, Camidge DC, Hill KM, House AO, Hulme CT 
University of Leeds, Leeds, UK  
OBJECTIVES: The use of financial incentives and disincentives is being explored 
as a way to encourage people to adopt healthier lifestyles. However, published 
methodological research in this area is limited. The objective was to explore the 
acceptability and pricing of incentives in NHS patients. METHODS: A contingent 
valuation survey was completed by patients who recently had a (confirmed or 
suspected) cardiac event and who either smoked, were overweight, physically 
inactive or abused alcohol. Respondents completed questions on health 
behaviour, perceived difficulty of behaviour change, minimum incentive 
required to motivate behaviour change along with attitudinal questions 
(incentive acceptability, motivation, perceived risk) and items on income and 
time preference. RESULTS: The survey was completed by 132 patients (39% 
Female; Mean age=59). A majority - 65% - did not agree that incentives should be 
offered by the NHS. There was a trend for males (p=.064) and higher income 
groups (p=.026) to be less in favour of incentives. Mean incentive levels required 
to help stop smoking, lose weight, exercise and reduce alcohol consumption 
were £88, £46, £57 and £30 per month, respectively. This represented 11%, 6%, 
10% and 4% of monthly household income, respectively. The minimum required 
incentive increased with higher levels of perceived change difficulty and 
decreased with higher reported motivation to change. Mean incentive levels 
required to stop smoking were: £18, £43 and £116; and for weight loss: £25, £53, 
and £62 for those perceiving change as easy, moderate and difficult, respectively. 
CONCLUSIONS: This preliminary analysis is one of the few to provide incentive 
pricing data and may prove useful in designing future incentive schemes. Incentive 
schemes may need to be targeted to the individual, taking into account (inter alia) 
their income, perceived difficulty of change and motivation levels. Future studies 
should explore targeted incentive pricing strategies on behaviour change.  
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THE IMPACT OF GENERIC DRUG POLICY ON DRUG PRICING  
Lee B1, Garay OU2, Goldhaber-Fiebert J3, Wilson LS1 
1University of California, San Francisco, San Francisco, CA, USA, 2Institute for Clinical Effectiveness and 
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OBJECTIVES: Medication access due to lack of affordability remains an issue in 
many Latin American countries. “The Generic Law” enacted in Argentina in 2002 
mandated that all prescribers write prescriptions with the active ingredient 
(International Nonproprietary Name, INN) instead of brand names. This study 
determined the effects of this policy on drug pricing in Argentina by comparing 
price and utilization trends of brand and generic drugs pre- and post-policy 
implementation. METHODS: Analyses included IMS data of annual WHO 
essential drug prices in Argentina from 1995-2010 and exclude those drugs with 
fewer than 4 years of price data. We compared generic and brand average annual 
price trends before and after policy implementation for 32 essential drugs, 
accounting for inflation resulting from an economic crisis in the year before the 
policy took effect. RESULTS: While actual price still increased, there was a 
decreased rate of change immediately after the policy change in both generic 
and brands of 22 drugs. Ten drugs did not exhibit the expected decrease in price 
trend; mainly antibiotics or drugs with a market competition of less than 10 or 
greater than 30 generic products. Available utilization data showed demand 
decreased as price rose, depending on market competition. CONCLUSIONS: In 
the years following implementation of The Generic Law, the rate of price change 
decreased for both brand and generic drugs. This research provides evidence to 
support the effectiveness of the generic policy in Argentina in controlling out-of-
pocket expenditure increases for medication. However, since this policy was 
enacted under specific market conditions, additional research must be 
conducted in other countries with a generic policy to confirm the observed 
outcomes.  
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Development, Raritan, NJ, USA  
Anticoagulant treatment is the mainstay for stroke prevention in atrial 
fibrillation (AF); however, the increased risk of bleeding caused by anticoagulants 
requires considering benefit-risk tradeoffs in their use. Patient and physician 
preferences for avoiding death, stroke and bleeding underlie these 
considerations and influence treatment decisions. OBJECTIVES: To quantify and 
compare US patient and physician preferences for benefits and risks associated 
with anticoagulants in AF. METHODS: Adult patients with a self-reported 
physician diagnosis of AF, and board-certified internists or cardiologists treating 
AF patients, completed a web-based, choice-format conjoint survey. Tradeoff 
questions in the survey included a pair of hypothetical anticoagulants defined by 
a risk profile including disabling and non-disabling stroke, myocardial infarction, 
embolism, and major and non-major clinically-relevant bleeding. Patients chose 
anticoagulants for themselves, while physicians chose anticoagulants for virtual 
patients. Random-parameters logit was used to estimate relative preference 
weights for the likelihood of experiencing outcomes. RESULTS: 186 patients 
(mean age 65.6) and 107 physicians completed the survey. Patients considered 
disabling stroke as the least desirable outcome, while physicians regarded death 
as least desirable. Relative to the risk of disabling stroke, patients considered 
death 60% (95% CI 39%-80%) as important, and non-fatal major bleeding and 
non-major clinically-relevant bleeding 47% (28%-65%) and 17% (10%-23%) as 
important, respectively. For physicians, relative to the risk of disabling stroke, 
death was 150% (82%-218%) as important, and non-fatal major bleeding and non-
major clinically-relevant bleeding were 66% (47%-84%) and 14% (8%-20%) as 
important. Non-fatal embolism and myocardial infarction were of intermediate 
importance between the two levels of bleeding for both groups. CONCLUSIONS: 
US patient decisions on anticoagulant treatment in AF may be more motivated 
by avoiding strokes, while physicians may focus more on avoiding death. The 
difference in perspective on relative importance of bleeding and stroke may lead 
to different benefit-risk assessments by patients and physicians.  
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OBJECTIVES: Heart failure (HF) is associated with increased risk of dementia and 
dementia is an independent predictor of mortality and hospitalization in HF 
patients. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs) may lower the risk of dementia by regulating the renin 
angiotensin system in the brain. Given the significant clinical impact of 
dementia associated with HF and the current urgency for effective treatments to 
reduce the incidence of dementia, the present study examines the effectiveness 
of ACEIs/ARBs that are widely prescribed for the treatment of HF. METHODS: 
This retrospective, longitudinal study used a cohort of patients with HF 
identified from a local Medicare advantage prescription drug plan to examine 
incidence of dementia with up to 3 years of follow up period. Multivariable time 
dependent Cox model and inverse-probability-of-treatment weighting (IPTW) of 
marginal structural model were used to estimate the risk of developing dementia 
controlling for sociodemographic factors, comorbidities, comedications, 
appropriate laboratory measures, and potential time-varying confounding 
affected by previous treatment (hospitalization). Adjusted dementia rate ratios 
were estimated among current and former ACEI/ARB users, as compared with 
nonusers. RESULTS: The study included a total of 8062 HF patients (mean age 
74.47 ±9.21 years) of which 1135 (14.08 %) patients were diagnosed with dementia 
during the median follow up of 22 months. Using the time dependent Cox model, 
the adjusted dementia rate ratios (95% confidence interval) among current and 
former users were 0.90 (0.70 - 1.16) and 0.89 (0.71 - 1.10). Use of IPTW resulted in 
similar effect estimates (95% conservative confidence interval) of 0.99 (0.74 - 1.32) 
among current users and 0.80 (0.59 - 1.08) for former users as compared with the 
nonusers. CONCLUSIONS: This study found no difference in risk of dementia 
among the current and former users of ACEI/ARB as compared with the nonusers 
in an already at-risk HF population.  
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SULFONYLUREAS ARE ASSOCIATED WITH ELEVATED RISK OF HIP FRACTURES 
AMONG ELDERLY MEN AND WOMEN WITH TYPE-2 DIABETES  
Rajpathak SN1, Fu C1, Engel SS1, Brodovicz KG1, Lapane K2 
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OBJECTIVES: Both increased age and type-2 diabetes are risk factors for 
developing bone fractures. While recent data in elderly diabetic individuals 
suggest a link between hypoglycemia and elevated risk of fall-related fractures, 
the association between sulfonylureas (SU), commonly used hypoglycemic 
agents, and fracture risk is not well investigated. METHODS: We conducted a 
study to evaluate the association between SU and risk of developing hip fracture 
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using Ingenix® data (2002-05). The analysis included elderly individuals aged ≥65 
years (47.9% females) on oral treatment for diabetes (insulin users excluded), 
classified as SU users (n=20,741) and non-users (n=22,114) at baseline. RESULTS: 
During the follow-up, we identified 420 cases of incident hip fractures in the SU 
group and 228 in non-SU group; unadjusted odds ratio (OR) for hip fracture risk 
was 1.98 (95% confidence intervals [CI]:1.69-2.33). In a multivariable logistic 
regression analysis simultaneously accounting for propensity to use SU and for 
potential confounders (age, gender, health insurance, geographic region, CVD, 
stroke, osteoporosis, dementia, hypertension, and use of steroids, 
benzodiazepines, anti-depression, anti-psychotic, anti-convulsant therapy and 
treatment for osteoporosis), the adjusted OR was 1.60 (95%CI: 1.35-1.90). This 
association was similar among men (210 cases; OR=1.68; 95%CI: 1.24-2.26) and 
women (438 cases; OR: 1.56; 95%: 1.27-1.92). In addition, SU users also had higher 
risk of hypoglycemia compared to non-users (5.8% vs. 2.1%). Furthermore, 
hypoglycemia was more common among hip fracture cases (12.0%) compared to 
non-cases (3.8%); the multivariable OR for hypoglycemia-fracture association 
adjusted for the above covariates was 1.81 (95% CI: 1.40-2.34). CONCLUSIONS: 
These results suggest that SU may be associated with increased risk of hip 
fracture in elderly men and women with diabetes, possibly related to elevated 
risk of hypoglycemia-induced falls. These findings need to be confirmed in 
future studies which should also further investigate the interrelationships of SU 
use with hypoglycemia, falls and fractures.  
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OBJECTIVES: Evaluate the external predictive power of the REVEAL HCV risk-
prediction model for HCC using data from the Veterans’ Administration [VA]. 
METHODS: The REVEAL investigators in Taiwan developed a risk-prediction 
model for HCC which has not been validated outside of Taiwan. The VA 
maintains a Clinical Case Registry [CCR] for approximately 360,000 patients with 
HCV infections which summarizes the utilization, diagnostic and lab value data 
for each patient going back to 1999. The patient’s initial HCV diagnosis date is set 
as the index date. VA patients were selected using the REVEAL 
inclusion/exclusion criteria and were then screened for baseline [+/- 6 months of 
index date] data on ALT, ALT/AST ratio, cirrhosis, HCV viral load and genotype. 
The area under ROC was used to evaluate the performance of the risk models. 
RESULTS: A totoal of 47,578 VA HCV patients met study inclusion criteria. The 
VA sample varied significantly from the REVEAL sample in terms of male gender 
and race. The frequency of a baseline viral load > 23,000 IU/mL was 91% in the 
VA sample versus 35% Taiwan sample. The overall incidence of HCC following a 
5-year washout period was 2.1% [n=1,000]. Average REVEAL HCV risk scored 13.2 
[SD=2.4] for non-HCC patients and 14.9 [SD=2.4] in patients with HCC [p<0.0001]. 
The incidence of HCC in VA patients increased monotonically across risk score 
quintiles: 0.48% for the lowest quintile to 4.3% for the highest quintile of risk 
scores. The area under the ROC was 0.6924 when the REVEAL HCV model was 
applied to VA patients. CONCLUSIONS: HCV risk prediction models help 
physicians to identify and motivate high risk patients to initiate treatment. The 
REVEAL risk prediction model is robust even when used for VA patients who 
differ significantly from the Taiwan sample from which the risk score model was 
estimated.  
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OBJECTIVES: To evaluate health care costs of patients with schizophrenia and 
specific comorbidities relative to patients without schizophrenia with the same 
comorbidities. METHODS: Medicaid insurance claims databases from five states 
(from 2001-2010) were analyzed. Adults with ≥2 claims for schizophrenia, ≥12 
months of continuous eligibility prior to the first diagnosis (index date), and ≥1 
claim for important comorbidities (substance abuse, obesity, diabetes, metabolic 
syndrome, hyperlipidemia, hypertension, coronary artery disease, congestive 
heart failure, HIV, hepatitis C, and COPD) during the 12 months prior to the index 
date (baseline period) were selected. Patients with schizophrenia were matched 
1:1 with non-schizophrenia control patients based on baseline characteristics 
(propensity scores) and comorbidities common in schizophrenia (exact matching 
factors). All-cause and comorbidity-related monthly health care costs were 
calculated and compared between cohorts using nonparametric re-resampling 
methods. No adjustment was made for multiplicity. RESULTS: A total of 24,652 
schizophrenia and 24,652 patients without schizophrenia were matched. The 
most common comorbidities were hypertension (48.8%), substance abuse (39.1%), 
and diabetes (28.4%). The patients with schizophrenia incurred greater all-cause 
monthly health care costs (cost difference [95% CI], $978 [933-1,024]) and 
comorbidity-related costs (cost difference [95% CI], $288 [269-307]). Schizophrenia 
was also associated with significantly higher comorbidity-related costs in each 
comorbidity subgroup (among the three most common comorbidities: 99% higher 
in hypertension, 293% in substance abuse, and 105% in diabetes). CONCLUSIONS: 
This study show that patients with schizophrenia and comorbidities common in 
patients with schizophrenia had higher all-cause and comorbidity-related health 
care costs compared with patients without schizophrenia with the same 
comorbidities.  
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OBJECTIVES: Estimate annual per-patient medical, drug, and work-loss costs of 
diabetic foot ulcer (DFU) using de-identified administrative claims data. 
METHODS: DFU patients and non-DFU diabetic patients (controls) were 
identified using two databases: ages 65+ from a 5% random sample of Medicare 
beneficiaries (Standard Analytical Files, 2007-2010; DFU N=29,681, controls N= 
201,757) and ages 18-64 from a privately-insured population (OptumInsight, 
2007-2011; DFU N=5,681, controls N=113,337). Patients were required to be 
continuously eligible during the 12 months before (baseline) and 12 months after 
(study period) the index date (ie, the date of the most recent DFU diagnosis 
following 12 months without DFU diagnoses (DFU group); or the date of a 
random medical claim (controls)). DFU patients were matched to controls using 
propensity scores to account for baseline differences in demographics, 
comorbidities, resource utilization, and costs. Medical costs during the study 
period were calculated for both Medicare and privately-insured patients. Because 
drug and work-loss (absenteeism or disability) data were not available for 
Medicare patients, these costs were estimated for the privately-insured sample 
only. Wilcoxon signed-rank tests were used to compare differences in study 
period costs. RESULTS: Data for 4,536 matched pairs of privately-insured  
and 27,878 matched pairs of Medicare patients were analyzed. Incremental 
medical costs for DFU patients were $11,296 for Medicare ($27,040 vs $15,743) and 
$15,329 for privately-insured ($25,931 vs $10,602) patients. Two-thirds (66%) of 
the cost differential among the privately-insured was attributable to excess 
inpatient costs. For Medicare, all places of services (eg, inpatient, 
outpatient/physician, emergency department) contributed approximately 
equally to the medical cost differential. Among the privately-insured, DFU 
patients had excess drug costs of $958 ($4,377 vs $3,420) and excess work-loss 
costs of $3,053 (absenteeism: +$1,490, disability: +$1,564). (Comparisons 
significant at p<0.0001.) CONCLUSIONS: These findings suggest that presence of 
DFU imposes substantial burden on payers beyond that of standard diabetes 
care.  
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OBJECTIVES: Previous research demonstrated that in some patients taking 
opioid analgesics for chronic pain there were significantly higher costs among 
those with concurrent exposures to CYP450-metabolized medications with the 
potential to cause a drug-drug interaction (pDDI), compared to matched patients 
without such exposures. The objectives of this study are to evaluate the 
prevalence of and health care costs associated with pDDIs that may cause major 
interactions in patients chronically taking long-acting opioid (LAO) analgesics. 
METHODS: Using the MarketScan® Commercial Database (2008-2010), cohorts 
were constructed of patients who were dispensed LAOs for >=30 days, both with 
and without pDDI exposures. Propensity score matching was used to mitigate 
the impact of selection bias. Costs were analyzed with a linear model for 
differences and a generalized linear model for ratios. RESULTS: Based on the 
final sample of 57,752 patients, the prevalence of major pDDIs was 5.7% in the 
90-day observation period. Oxycodone was the most common opioid among 
these pDDIs pairs, accounting for 57.3% of patients, followed by fentanyl (32.9%), 
methadone (18.3%) and codeine (1.8%). The most common precipitant drugs 
were fluconazole (34.5%), diltiazem (14.0%), clarithromycin (11.4%) and verapamil 
(10.9%). Based on the 99th percentile cost cutoff in the propensity score matched 
cohorts, the estimated mean monthly overall health care costs from the 
multivariate linear model were $3366 and $2757 for the pDDI-major cohort and 
no-pDDI cohort, respectively, a $609 difference. The generalized linear model 
provided similar results, with an estimated cost ratio of 1.232 (p-value < 0.01). 
The difference in monthly health care cost was mainly driven by outpatient 
medical cost ($257 difference, ratio 1.219, p- value <0.01) and inpatient medical 
cost ($289 difference, p-value = 0.11). CONCLUSIONS: Among patients chronically 
taking LAO analgesics, the exposure to major pDDIs is costly and worthy of 
efforts to avoid such exposures.  
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OBJECTIVES: Propensity score (PS) is widely used in observational study. It is 
usually estimated over entire study time period. However, pattern of medication 
use is changed over time. The PS which is estimated without taking into account 
time might be biased. Little is known about the effects of time on propensity 
score. This study aims to determine the differences of PS estimated by 
conventional PS and time-specific PS approaches and their effects on estimates 
of treatment effects. METHODS: A retrospective database analysis at a 
University-affiliated hospital in Thailand was used. Patients who aged 18 years 
